2007 Competition Patients 
pharmaphorum
DECEMBER 14, 2022
When patients experience intense emotion, either positive or negative, they are rendered unconscious. But increased competition is on the horizon. Both the physician and the patient have to be registered and the drugs can only come from a primary source through limited distribution. Competition starts to heat up.
Evolve Your Success
MARCH 14, 2023
This is 2007. You are so spoiled if you are trying to get into this now because there’s competition in this space for you to reach that next level. It was like, “I need to get as many patients that have this condition to him, and he will give it as an option.” They are taking phone calls from patients directly a lot.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 19, 2023
Globally, the first rituximab biosimilar, Dr Reddy’s Laboratories’ Reditux, was approved in India in 2007. However, in the second year of biosimilar competition, Rituxan sales started to significantly erode. Rituxan’s success made it a prime target for biosimilar developers.
Pharmaceutical Technology
FEBRUARY 24, 2023
The overhaul will address drug marketing exclusivity length, pricing, patient access, innovation incentives, antimicrobial resistance, clinical trials, supply chain security and shortages, and environmental impact. EU competitiveness Moll said the legislation revisions should instead be used to make Europe more attractive to pharma companies.
pharmaphorum
AUGUST 3, 2022
Lucentis was first approved in the US in 2007 for wet AMD and grew quickly thereafter as additional indications were approved. Coherus’ chief commercial officer Paul Reider said the availability of Cimerli will “provide both greater treatment access and choice for patients, payors and providers in the US retinal disease community.”
pharmaphorum
JANUARY 16, 2023
Across swathes of primary care, pharmacological innovation has stalled; the last new antihypertensive class was introduced in 2007 and new antibiotics have trickled in at a dangerously slow pace. More approvals, in larger patient population conditions will elevate the ongoing discussion of how to pay for these therapies.
pharmaphorum
JULY 15, 2022
The case hinges around the concept of “ skinny labelling ” which was introduced to stop drugmakers extending the exclusivity period for their branded medicines – through a stream of new indications or patient populations – that can be protected with so-called “use” patents. The substance patent expired in 2007.
Expert insights. Personalized for you.
116 
Let's personalize your content